AxoGen, Inc.
NASDAQ:AXGNMedical - Devices
+$0.25 today
- Market cap
- $3.40B
- Beta
- 1.12
- P/E (TTM)
- -73.4
- EPS (TTM)
- -$0.61
Volume 2.11M
Average 1.08M
AXGN Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
AxoGen, Inc.NASDAQ: AXGN
Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026
Accounts receivables turns positive
Q3 FY2026 accounts receivables was $62K, compared with -$2.72M a year earlier. Trailing-twelve-month accounts receivables was -$3.28M. Over 3 fiscal years it compounded at -19.0% a year.
Context
- Accounts receivables amounted to 1.1% of revenue in FY2025, up 0.9 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near $62K or moves back toward the trailing-twelve-month quarterly average of -$819.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (2.46M) USD
- Year-over-year change
- -728.6%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.46M) | -728.6% |
| FY2024 | 2024-12-31 | 392K | +114.6% |
| FY2023 | 2023-12-31 | (2.69M) | +42.0% |
| FY2022 | 2022-12-31 | (4.64M) | -829.7% |
| FY2021 | 2021-12-31 | (499K) | — |
Accounts Receivables vs competitors
How AXGN compares with its peers on the latest reported figures
- AXGN's LTM Sep 2026 accounts receivables of $3.28M is the 4th largest of the 7 companies compared; the peer median is $780.5K.
- Its year-over-year change of -49.9% is the 6th highest of 7, against a peer median of +147.2%.
- Accounts receivables amounts to 1.2% of revenue for AXGN, versus a peer median of 2.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $29.63M | -386.2% | +156.4% | — | |
| LTM Mar 2026 | $16.97M | +54.1% | +136.4% | 3.3% | |
| LTM Mar 2026 | $9.02M | +240.7% | +64.4% | 2.3% | |
| LTM Sep 2026 | $3.28M | -49.9% | -19.0% | 1.2% | |
| LTM Mar 2026 | $2.97M | +199.2% | -46.9% | 2.4% | |
| LTM Jun 2026 | $1.51M | +176.9% | -64.3% | 1.9% | |
| LTM Mar 2026 | $54K | +117.5% | — | 2.7% | |
| Peer median (excluding AXGN) | $780.5K | +147.2% | +64.4% | 2.4% | |
Competitors are the stored peer set for AXGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.99M) | (28.95M) | (21.72M) | (9.96M) | (15.7M) |
| Depreciation & Amortization | 4.74M | 4.85M | 5.55M | 7.84M | 8.19M |
| Deferred Income Tax | 3.37M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.92M | 15.59M | 14.42M | 15.91M | 30.11M |
| Change in Working Capital | (6.28M) | (9.56M) | (4.39M) | (10.04M) | (24.62M) |
| Accounts Receivables | (499K) | (4.64M) | (2.69M) | 392K | (2.46M) |
| Inventory | (7.48M) | (3.66M) | (6.05M) | (10.16M) | (9.19M) |
| Accounts Payables | (270K) | 660K | 6.51M | 125K | (7.16M) |
| Other Working Capital | 1.97M | (1.93M) | (2.15M) | (399K) | (5.81M) |
| Other Non-Cash Items | 831K | 2M | 415K | 797K | 2.83M |
| Operating Cash Flow | (13.41M) | (16.07M) | (5.72M) | 4.54M | 812K |
| Capital Expenditures | (28.4M) | (21.25M) | (14.92M) | (4.52M) | (3.75M) |
| Acquisitions (Net) | (589K) | 3.2M | 0 | 0 | 0 |
| Purchases of Investments | (68.7M) | (39.25M) | (10.2M) | (5.77M) | (13.72M) |
| Sales of Investments | 72.5M | 57.3M | 44.37M | 0 | 14M |
| Other Investing Activities | 1.54M | (3.2M) | (1.05M) | (1.42M) | (1.85M) |
| Investing Cash Flow | (23.65M) | (3.2M) | 19.25M | (10.3M) | (5.32M) |
| Debt Repayment | 14.99M | (12K) | (10K) | (10K) | (32K) |
| Common Stock Issued | 5.47M | 1.81M | 1.96M | 2.3M | 10.53M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 20.45M | 1.79M | 1.95M | 2.29M | 10.5M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (16.6M) | (17.47M) | 15.49M | (3.47M) | 5.99M |
| Free Cash Flow | (41.81M) | (37.32M) | (20.63M) | 11K | (2.93M) |
AxoGen, Inc.
NASDAQ:AXGN
Intrinsic Alpha fair value
Locked
Current Price
$56.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.